# Souffle Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/souffle-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.souffletx.com
- Total disclosed funding: $335M
- Latest round: Series B (Oct 16, 2026)
- Investors on record: 17

## About

Based in Watertown, US, Souffle Therapeutics, Inc. focuses on developing innovative nucleic acid medicines aimed at treating genetic disorders, particularly in muscle and heart conditions.Souffle Therapeutics, founded in 2021 and headquartered in Watertown, US, specializes in the development of targeted nucleic acid therapies. The company raised USD 200.00 mn in Series A funding on October 7, 2025, from investors including ARCH Venture Partners, Bessemer Venture Partners, Polaris Partners, Leaps by Bayer, and Vida Ventures. The firm has completed one deal to date, marking its entry into the biopharmaceutical sector. Souffle Therapeutics specializes in the development of nucleic acid medicines designed to precisely target and enter cells implicated in disease processes. The core product offerings focus on therapies for conditions such as Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically driven cardiomyopathies, specifically targeting the phospholamban (PLN) gene mutation. These innovative treatments utilize engineered cell-specific ligands to facilitate the delivery of small interfering RNA (siRNA) across cell membranes, thereby modulating gene and protein levels to reverse disease states. The company is laying the groundwork for clinical trials set to begin in 2026, with the potential to serve diverse patient populations suffering from muscle dystrophies, heart failure, and metabolic disorders, targeting markets globally with a specific focus on North America, Europe, and Asia.Souffle Therapeutics has successfully raised over USD 3.50 bn through various capital ventures and collaboration agreements with pharmaceutical partners and healthcare investors. Revenue generation is primarily structured through partnerships and collaborations with leading biotech and pharmaceutical companies focused on the development of genetic medicines. These transactions often involve B2B agreements, where Souffle provides its proprietary technology and expertise in nucleic acid therapies to enhance partners' product pipelines. The financial framework encompasses milestone payments and royalties associated with the commercialization of their therapies, ensuring a sustainable revenue stream while advancing their therapeutic offerings. Key products, including those targeting FSHD and PLN mutations, are anticipated to drive interest from healthcare providers and payers once they enter the market, highlighting the company's potential for long-term growth in the biopharmaceutical landscape. In October 2025, Souffle Therapeutics raised USD 200.00 mn in Series A funding, which will be utilized to develop targeted, cell-specific siRNA medicines and advance lead programs into the clinic by 2026. The company plans to initiate clinical trials for its therapies in 2026, with a strategic focus on expanding its presence in North America, Europe, and Asia, thereby addressing significant unmet medical needs in these regions.

## Funding rounds

- Series B, Oct 16, 2026, $135M — Juvia Group, Arch Venture Partners, Balyasny Asset Management, BB Biotech, Bessemer Venture Partners, Breyer Capital, Fidelity, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, TCG Crossover Management, Temasek, The Invus Group, Amgen Ventures, Vida Ventures
- Series A, Oct 7, 2025, $200M — ARCH Venture Partners, Polaris Partners, Bessemer Venture Partners, Vida Ventures, Leaps by Bayer

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- Juvia Group (https://capitalatlas.ai/funds/juvia-group) — Series B
- Balyasny Asset Management — Series B
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series B
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series B
- Fidelity — Series B
- Janus Henderson (https://capitalatlas.ai/funds/janus-henderson) — Series B
- Safar Partners (https://capitalatlas.ai/funds/safar-partners) — Series B
- TAS Partners — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Temasek — Series B
- The Invus Group — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B